This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (63)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Carol K. Kasper, MD; Shelby L. Dietrich, MD; Samuel I. Rapaport, MD

Arch Intern Med. 1970;125(6):1004-1009.

Abstract
Antihemophilic factor concentrate was given on fixed schedules to adults with severe classic hemophilia who had very frequent hemorrhages. While receiving 250 factor VIII units a day, the subjects had almost half as many bleeding episodes as during a baseline period; on a regimen of 500 factor VIII units a day, bleeding episodes occurred about one fourth as often as during the baseline period. When a large dose, 2,000 factor VIII units, was given once a week, no bleeding episodes occurred in the first 48 hours, but occurred again in midweek when factor VIII levels had returned to baseline values. Prophylaxis in hemophilia with factor VIII concentrate is feasible and beneficial; the expense may not be much greater than that of treating random hemorrhages.

Author Affiliations
Los Angeles

From the Department of Medicine, University of Southern California School of Medicine, and the Regional Hemophilia Rehabilitation. Center, Orthopaedic Hospital, Los Angeles.

Footnotes
Received for publication Aug 27, 1969; accepted Feb 24, 1970.

Read in part before the Twelfth Congress of the International Society of Hematology, New York, 1968.

Reprint requests to 2400 S Flower St, Los Angeles 90007 (Dr. Kasper).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Strategies for the Review of Transfusion Practices
Silberstein et al.
JAMA 1989;262:1993-1997.
ABSTRACT  

Hemophilia Prophylaxis
JAMA 1970;212:2256-2257.
ABSTRACT